Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906642016> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2906642016 endingPage "S128" @default.
- W2906642016 startingPage "S128" @default.
- W2906642016 abstract "In type 2 diabetes (T2D) patients with established CV disease, empagliflozin reduced heart failure hospitalizations (HHF) and CV death compared to SoC, regardless of HF at baseline. Given the poor outcomes and economic burden of these comorbidities, we investigated the cost-effectiveness of empagliflozin on top of SoC in T2D patients with HF at baseline over a lifelong time horizon from a UK perspective. Discrete event simulation economic model was developed to project CV events including HHF, CV death, and kidney outcomes for EMPA-REG OUTCOME T2D patients with HF at baseline. Respective risk equations were derived using event-free survival curves with time-dependent covariates. Model validity was assessed by comparing predicted and observed outcomes at three years. UK unit costs of complications and QoL data were obtained from literature. The drug costs were from the British National Formulary and Monthly Index of Medical Specialties. Outcomes included event rates per 100 patient-years (PYs), life years (LYs), costs, and quality-adjusted life years (QALYs). Patients on empagliflozin were projected to experience fewer events of 1st HHF (3.64 vs 4.61 per 100 PY) and recurrent HHF (2.78 vs 4.92 per 100 PY), CV deaths (6.07 vs 7.37 per 100 PY), and non-fatal MI (2.67 vs 3.31 per 100 PY), but higher event rate for non-fatal stroke (2.57 vs 1.54 per 100 PY), compared to SoC. Treatment with empagliflozin projected 1.22 LYs and 0.65 QALYs gained. Incremental Cost-Effectiveness Ratio (ICER) for empagliflozin compared with SoC was £434/QALY. Probabilistic sensitivity analyses suggested that the probability of empagliflozin being cost-effective in patients with T2D and HF at a threshold of £20,000/QALY was 89%. Based on results of EMPA-REG OUTCOME, this cost effectiveness analysis suggests that empagliflozin on top of SoC is a cost-effective treatment option for patients with T2D and chronic HF from the UK NHS perspective." @default.
- W2906642016 created "2019-01-01" @default.
- W2906642016 creator A5003188866 @default.
- W2906642016 creator A5003810679 @default.
- W2906642016 creator A5016763799 @default.
- W2906642016 creator A5028502811 @default.
- W2906642016 creator A5030578368 @default.
- W2906642016 creator A5034066967 @default.
- W2906642016 creator A5060236174 @default.
- W2906642016 creator A5073440750 @default.
- W2906642016 creator A5074225876 @default.
- W2906642016 creator A5081421617 @default.
- W2906642016 creator A5082520060 @default.
- W2906642016 date "2018-10-01" @default.
- W2906642016 modified "2023-09-23" @default.
- W2906642016 title "PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM" @default.
- W2906642016 doi "https://doi.org/10.1016/j.jval.2018.09.768" @default.
- W2906642016 hasPublicationYear "2018" @default.
- W2906642016 type Work @default.
- W2906642016 sameAs 2906642016 @default.
- W2906642016 citedByCount "2" @default.
- W2906642016 countsByYear W29066420162020 @default.
- W2906642016 countsByYear W29066420162022 @default.
- W2906642016 crossrefType "journal-article" @default.
- W2906642016 hasAuthorship W2906642016A5003188866 @default.
- W2906642016 hasAuthorship W2906642016A5003810679 @default.
- W2906642016 hasAuthorship W2906642016A5016763799 @default.
- W2906642016 hasAuthorship W2906642016A5028502811 @default.
- W2906642016 hasAuthorship W2906642016A5030578368 @default.
- W2906642016 hasAuthorship W2906642016A5034066967 @default.
- W2906642016 hasAuthorship W2906642016A5060236174 @default.
- W2906642016 hasAuthorship W2906642016A5073440750 @default.
- W2906642016 hasAuthorship W2906642016A5074225876 @default.
- W2906642016 hasAuthorship W2906642016A5081421617 @default.
- W2906642016 hasAuthorship W2906642016A5082520060 @default.
- W2906642016 hasBestOaLocation W29066420161 @default.
- W2906642016 hasConcept C112930515 @default.
- W2906642016 hasConcept C126322002 @default.
- W2906642016 hasConcept C134018914 @default.
- W2906642016 hasConcept C138411078 @default.
- W2906642016 hasConcept C144024400 @default.
- W2906642016 hasConcept C149923435 @default.
- W2906642016 hasConcept C185592680 @default.
- W2906642016 hasConcept C194828623 @default.
- W2906642016 hasConcept C199289684 @default.
- W2906642016 hasConcept C2775887513 @default.
- W2906642016 hasConcept C2777180221 @default.
- W2906642016 hasConcept C2779900020 @default.
- W2906642016 hasConcept C2780652884 @default.
- W2906642016 hasConcept C3019080777 @default.
- W2906642016 hasConcept C515549039 @default.
- W2906642016 hasConcept C555293320 @default.
- W2906642016 hasConcept C71924100 @default.
- W2906642016 hasConceptScore W2906642016C112930515 @default.
- W2906642016 hasConceptScore W2906642016C126322002 @default.
- W2906642016 hasConceptScore W2906642016C134018914 @default.
- W2906642016 hasConceptScore W2906642016C138411078 @default.
- W2906642016 hasConceptScore W2906642016C144024400 @default.
- W2906642016 hasConceptScore W2906642016C149923435 @default.
- W2906642016 hasConceptScore W2906642016C185592680 @default.
- W2906642016 hasConceptScore W2906642016C194828623 @default.
- W2906642016 hasConceptScore W2906642016C199289684 @default.
- W2906642016 hasConceptScore W2906642016C2775887513 @default.
- W2906642016 hasConceptScore W2906642016C2777180221 @default.
- W2906642016 hasConceptScore W2906642016C2779900020 @default.
- W2906642016 hasConceptScore W2906642016C2780652884 @default.
- W2906642016 hasConceptScore W2906642016C3019080777 @default.
- W2906642016 hasConceptScore W2906642016C515549039 @default.
- W2906642016 hasConceptScore W2906642016C555293320 @default.
- W2906642016 hasConceptScore W2906642016C71924100 @default.
- W2906642016 hasLocation W29066420161 @default.
- W2906642016 hasOpenAccess W2906642016 @default.
- W2906642016 hasPrimaryLocation W29066420161 @default.
- W2906642016 hasRelatedWork W2312864767 @default.
- W2906642016 hasRelatedWork W2588682962 @default.
- W2906642016 hasRelatedWork W2610912351 @default.
- W2906642016 hasRelatedWork W2766567199 @default.
- W2906642016 hasRelatedWork W2893676915 @default.
- W2906642016 hasRelatedWork W2906462614 @default.
- W2906642016 hasRelatedWork W2906642016 @default.
- W2906642016 hasRelatedWork W2948388410 @default.
- W2906642016 hasRelatedWork W3021684010 @default.
- W2906642016 hasRelatedWork W3085325173 @default.
- W2906642016 hasVolume "21" @default.
- W2906642016 isParatext "false" @default.
- W2906642016 isRetracted "false" @default.
- W2906642016 magId "2906642016" @default.
- W2906642016 workType "article" @default.